Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Fujifilm Investing $200M to Expand CDMO Services and Double Capacity for iPSC-derived Therapeutics

March 23, 2024 By Cade Hildreth, Founder & President Leave a Comment

The investment will double FUJIFILM Cellular Dynamics’s manufacturing capacity for iPSC-derived cell therapies for its partners. New headquarters will include iPSC manufacturing for drug discovery, drug efficacy, and pharmacology applications.

FUJIFILM Diosynth Biotechnologies’ site in Thousand Oaks, CA, will be expanded to support cell therapy CDMO services.

[Read more…]

ExoXpert, a CDMO launched by EXO Biologics to service increasing worldwide demand for exosomes

March 22, 2024 By Cade Hildreth, Founder & President Leave a Comment

Liege, Belgium – EXO Biologics SA, a Belgian biotech company committed to developing biopharmaceuticals using exosomes to treat rare diseases with high unmet medical needs, today announces the worldwide launch of ExoXpert^TM, a contract development and manufacturing organization (CDMO) specializing in exosomes. ExoXpert offers a MSC-based exosome manufacturing platform used in European clinical trials. ExoXpert is a wholly owned subsidiary of EXO Biologics^TM. [Read more…]

Deverra Therapeutics Granted FDA Regenerative Medicine Advanced Therapy and Orphan Drug Designations for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid Leukemia

March 20, 2024 By Cade Hildreth, Founder & President Leave a Comment

Designations Validate Preliminary Data and Enhances Ability to Offer Dilanubicel to Cancer Patients

SEATTLE, WA, March 19, 2024 – Deverra Therapeutics Inc., a clinical-stage biotechnology company developing allogeneic universal donor cell therapy treatments to fight cancer and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT)designation to its lead candidate (dilanubicel) for use in first-line treatment for acute myeloid leukemia (AML). [Read more…]

Kenai Therapeutics Emerges with $82M to Advance Its Allogeneic, iPSC-Derived Therapy for Parkinson’s Disease

March 14, 2024 By Cade Hildreth, Founder & President Leave a Comment

Kenai Therapeutics has emerged from stealth mode with $82M to invest in its allogeneic iPSC-derived cell therapeutic for Parkinson’s disease (PD).

Proceeds to be used to complete clinical proof-of-concept trial for Kenai’s lead candidate, RNDP-001, for the treatment of Parkinson’s disease.

Financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures.

[Read more…]

Waisman Biomanufacturing & RoosterBio Announce Collaboration for GMP Manufacturing of Cell & Exosome Therapies

March 13, 2024 By Cade Hildreth, Founder & President Leave a Comment

Madison, WI — Waisman Biomanufacturing, a leading contract development and manufacturing organization (CDMO) which is strategically part of the University of Wisconsin Madison, announced today a strategic partnership with RoosterBio, Inc., a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services. [Read more…]